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Summary
Routine vaccination of children is an effective way to reduce hepatitis A incidence in the United States. Since licensure of
hepatitis A vaccine during 1995–1996, the hepatitis A childhood immunization strategy has been implemented incrementally,
starting with the recommendation of the Advisory Committee on Immunization Practices (ACIP) in 1996 to vaccinate children
living in communities with the highest disease rates and continuing in 1999 with ACIP’s recommendations for vaccination of
children living in states, counties, and communities with consistently elevated hepatitis A rates. These updated recommendations
represent the final step in the childhood hepatitis A immunization strategy, routine hepatitis A vaccination of children nation-
wide. Implementation of these recommendations will reinforce existing vaccination programs, extend the benefits associated with
hepatitis A vaccination to the rest of the country, and create the foundation for eventual consideration of elimination of indig-
enous hepatitis A virus transmission.
This report updates ACIP’s 1999 recommendations concerning the prevention of hepatitis A through immunization (CDC.
Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immuniza-
tion Practices [ACIP]. MMWR 1999:48[No. RR-12]:1–37) and includes 1) new data on the epidemiology of hepatitis A in the
era of hepatitis A vaccination of children in selected U.S. areas, 2) results of analyses of the economics of nationwide routine
vaccination of children, and 3) recommendations for the routine vaccination of children in the United States. Previous recom-
mendations for vaccination of persons in groups at increased risk for hepatitis A or its adverse consequences and recommendations
regarding the use of immune globulin for protection against hepatitis A are unchanged from the 1999 recommendations.
persons in groups shown to be at high risk for infection and
children living in communities with high rates of disease (2).
In 1999, as the next step in a strategy of incremental imple-
mentation of recommendations for routine vaccination of
children, ACIP expanded the recommendations to include
vaccination of children living in states, counties, and commu-
nities in which hepatitis A rates were consistently above the
national average (3). Coincident with implementation of these
recommendations, hepatitis A rates have declined to the low-
est level ever recorded (4). Because declines were largest in the
areas in which routine vaccination of children was occurring,
rates are now more equivalent across regions, with the highest
rates occurring among children in parts of the country where
vaccination has not been recommended (5). This statement
includes recommendations for the final step in this incremen-
tal strategy, routine hepatitis A vaccination of children
nationwide. Implementation of these recommendations will
reinforce existing vaccination programs, extend the benefits
associated with hepatitis A vaccination to the rest of the coun-
try, and create the foundation for eventual consideration of
elimination of indigenous HAV transmission.
Introduction
During 1980–1995, approximately 22,000–36,000 cases of
hepatitis A were reported annually in the United States, rep-
resenting an estimated average of 271,000 infections per year
when anicteric disease and asymptomatic infections are taken
in account (1). During 1995–1996, highly effective hepatitis
A vaccines became available in the United States for use among
persons aged >2 years, providing an opportunity to reduce
hepatitis A incidence substantially and potentially eliminate
indigenous transmission of hepatitis A virus (HAV).
In 1996, the Advisory Committee on Immunization Prac-
tices (ACIP) first made recommendations to prevent hepatitis
A through immunization, focusing primarily on vaccinating
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Primary Changes in the Statement
Changes in recommendations include the following:
• updated data regarding the epidemiology of hepatitis A
since the advent of hepatitis A vaccination of children in
selected areas of the United States,
• results of recent economic analyses of nationwide routine
vaccination of children, and
• recommendations for the routine vaccination of children
aged >1 year in the United States.
Previous recommendations for 1) vaccination of persons in
groups at increased risk for hepatitis A or its adverse conse-
quences and 2) use of immune globulin (IG) for protection
against hepatitis A are unchanged (3).
Clinical and Diagnostic Features
of Hepatitis A
Clinical Illness
HAV, a 27-nm RNA agent classified as a picornavirus, can
produce either asymptomatic or symptomatic infection in
humans after an average incubation period of 28 days (range:
15–50 days) (6). Illness caused by HAV infection typically
has an abrupt onset that can include fever, malaise, anorexia,
nausea, abdominal discomfort, dark urine, and jaundice. The
likelihood of having symptoms with HAV infection is related
to age. In children aged <6 years, 70% of infections are
asymptomatic; if illness does occur, it is typically not accom-
panied by jaundice (7). Among older children and adults,
infection typically is symptomatic, with jaundice occurring
in >70% of patients (8). Signs and symptoms typically last
<2 months, although 10%–15% of symptomatic persons have
prolonged or relapsing disease lasting up to 6 months (9).
The overall case-fatality ratio among cases reported through
the National Notifiable Diseases Surveillance System is
approximately 0.3%–0.6% but reaches 1.8% among adults
aged >50 years; persons with chronic liver disease are at
increased risk for acute liver failure (5,10–15).
In infected persons, HAV replicates in the liver, is excreted in
bile, and is shed in stool. Peak infectivity of infected persons
occurs during the 2-week period before onset of jaundice or
elevation of liver enzymes, when concentration of virus in stool
is highest (16). Concentration of virus in stool declines after
jaundice appears. Children can shed HAV for longer periods
than do adults, lasting up to 10 weeks (17) after onset of clini-
cal illness; infants infected as neonates in one nosocomial out-
break shed HAV for up to 6 months (18). Chronic shedding of
HAV in feces does not occur; however, recurrent shedding
occurs during relapses among persons who have relapsing
illness (19). Viremia occurs soon after infection and persists
through the period of liver enzyme elevation, but at concentra-
tions several orders of magnitude lower than in stool (20,21).
Diagnosis
Hepatitis A cannot be differentiated from other types of
viral hepatitis on the basis of clinical or epidemiologic fea-
tures alone. Serologic testing to detect immunoglobulin M
(IgM) antibody to the capsid proteins of HAV (IgM anti-
HAV) is required to confirm a diagnosis of acute HAV infec-
tion. Sensitive tests for IgM and immunoglobulin G (IgG)
anti-HAV in saliva have been developed but are not licensed
in the United States (22). In the majority of persons, serum
IgM anti-HAV becomes detectable 5–10 days before onset of
symptoms (21,23). IgG anti-HAV, which appears early in the
course of infection, remains detectable for the person’s life-
time and provides lifelong protection against the disease. Two
serologic tests are licensed for the detection of antibodies to
HAV: 1) IgM anti-HAV and 2) total anti-HAV (i.e., IgM and
IgG anti-HAV, referred to in this report as anti-HAV) (24).
In the majority of patients, IgM anti-HAV declines to unde-
tectable levels <6 months after infection (23). However, per-
sons who test positive for IgM anti-HAV >1 year after infection
have been reported, as have likely false-positive tests in per-
sons without evidence of recent HAV infection (25–27).
Total anti-HAV testing is used in epidemiologic studies to
measure the prevalence of previous infection or by clinicians
to determine whether a person with an indication for pre-
exposure prophylaxis is already immune.
HAV RNA can be detected in the blood and stool of the
majority of persons during the acute phase of infection by
using nucleic acid amplification methods, and nucleic acid
sequencing has been used to determine the relatedness of HAV
isolates for epidemiologic investigations (28–30). However,
only a limited number of research laboratories have the
capacity to use these methods.
Epidemiology of Hepatitis A
Modes of Transmission
Person-to-person transmission through the fecal-oral route
is the primary means of HAV transmission in the United States.
Transmission occurs most frequently among close contacts,
especially in households and extended family settings (31).
Because the majority of children have asymptomatic or
unrecognized infections, they play a key role in HAV trans-
mission and serve as a source of infection for others (32,33).
In one study of adults without an identified source, 52% of
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their households included a child aged <6 years, and the pres-
ence of a young child was associated with HAV transmission
in the household (32). In studies in which serologic testing of
the household contacts of adults without an identified source
of infection was performed, 25%–40% of contacts aged
<6 years had serologic evidence of acute HAV infection (IgM
anti-HAV) (17,32).
Common-source outbreaks and sporadic cases also can
occur from exposure to fecally contaminated food or water.
Uncooked foods have been recognized frequently as a source
of outbreaks (34). Cooked foods also can transmit HAV if
cooking is inadequate to kill the virus or if food is contami-
nated after cooking, as occurs commonly in outbreaks associ-
ated with infected food handlers (34–37). Waterborne
outbreaks of hepatitis A are infrequent in developed countries
with well-maintained sanitation and water supplies. The
majority of waterborne outbreaks are associated with
sewage-contaminated or inadequately treated water (38–40).
Outbreaks in the context of floods or other natural disasters
(e.g., hurricanes) have not been reported in the United States.
Depending on conditions, HAV can be stable in the envi-
ronment for months (41). Heating foods at temperatures
>185°F (>85°C) for 1 minute or disinfecting surfaces with a
1:100 dilution of sodium hypochlorite (i.e., household bleach)
in tap water is necessary to inactivate HAV (42).
On rare occasions, HAV infection has been transmitted by
transfusion of blood or blood products collected from donors
during the viremic phase of their infection (20,43). Since 2002,
nucleic acid amplification tests such as polymerase chain reac-
tion (PCR) have been applied to the screening of source plasma
used for the manufacture of plasma-derived products (44).
In experimentally infected nonhuman primates, HAV has
been detected in saliva during the incubation period (45).
However, transmission by saliva has not been demonstrated.
Disease Patterns
Prevaccine Era
Hepatitis A epidemiology in the United States has funda-
mentally changed with licensure of hepatitis A vaccine and
implementation of national ACIP recommendations for its
use. Before vaccine licensure during 1995–1996, hepatitis A
incidence was primarily cyclic, with peaks occurring every
10–15 years. In the United States, during 1980–1995,
approximately 22,000–36,000 hepatitis A cases were reported
annually to CDC (rate: 9.0–14.5 cases per 100,000 popula-
tion), but incidence models indicate that the number of
infections was substantially higher (1,5). One such analysis
estimated an average of 271,000 infections per year during
1980–1999, representing 10.4 times the reported number of
cases (1). Each year in the United States, an estimated 100
persons died as a result of acute liver failure attributed to
hepatitis A.
The costs associated with hepatitis A are substantial. Sur-
veillance data indicate that 11%–22% of persons with hepa-
titis A are hospitalized (3). The average duration of work loss
for adults who become ill has been estimated at 15.5 days for
nonhospitalized patients and 33.2 days for hospitalized
patients (46). Estimates of the annual direct and indirect costs
of hepatitis A in the United States have ranged from $300
million to $488.8 million in 1997 dollars (3,46). A recent
Markov model analysis estimated economic costs of $133.5
million during the lifetime of a single age cohort of children
born in 2005, in the absence of vaccination (CDC, unpub-
lished data, 2005).
Variation by Age, Race/Ethnicity, and Region. During
the prevaccine era, the reported incidence of hepatitis A was
highest among children aged 5–14 years, with approximately
one third of reported cases involving children aged <15 years
(Figure 1) (5). Because young children frequently have unrec-
ognized or asymptomatic infection, a relatively smaller pro-
portion of infections among children than adults are detected
by routine disease surveillance. Incidence models indicate that
during 1980–1999, the majority of HAV infections occurred
among children aged <10 years, and the highest incidence
was among those aged 0–4 years (1). Before the use of hepati-
tis A vaccine, rates among American Indians and Alaska
Natives were more than five times higher than rates in other
racial/ethnic populations, and rates among Hispanics were ap-
FIGURE 1. Rate* of reported hepatitis A, by age group and
year — United States, 1990–2004
SOURCE: National Notifiable Diseases Surveillance System.
* Per 100,000 population.
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proximately three times higher than rates among non-His-
panics (Figure 2) (5,47–49).
Since the 1960s, the highest hepatitis A rates and the
majority of cases occurred in a limited number of states and
counties concentrated in the western and southwestern United
States (Figure 3) (4). Despite year-to-year fluctuations, rates
in these areas consistently remained above the national aver-
age. In 11 states (Alaska, Arizona, California, Idaho, Nevada,
New Mexico, Oklahoma, Oregon, South Dakota, Utah, and
Washington) with consistently elevated rates, representing 22%
of the U.S. population, average annual hepatitis A incidence
was >20 cases per 100,000 during 1987–1997 (twice the
national average of approximately 10 cases per 100,000 popu-
lation); cases among residents of these states accounted for an
average of 50% of reported cases (3). An additional 18% of
cases occurred among residents of six states (Arkansas, Colo-
rado, Missouri, Montana, Texas, and Wyoming) with average
annual rates above (but less than twice) the national average
during this time.
Approximately 31% of the U.S. population had serologic
evidence of previous HAV infection, when measured in the
Third National Health and Nutrition Examination Survey
(NHANES-III) conducted during 1988–1994 (50). Anti-
HAV prevalence varied directly with age: among persons aged
6–11 years, prevalence was 9%; 20–29 years, 19%; 40–49
years, 33%; and >70 years, 75%. Age-adjusted anti-HAV
prevalence was considerably higher among Mexican-
American (70%) compared with black (39%) and white (23%)
participants, and among foreign-born (69%) compared with
U.S.-born (25%) participants.
Sources of Infection. In the prevaccine era, the majority of
U.S. cases of hepatitis A resulted from person-to-person trans-
mission of HAV during communitywide outbreaks (31,51).
The most frequently reported source of infection (in 12%–
26% of cases) was household or sexual contact with a person
with hepatitis A (52). Cyclic outbreaks occurred among users
FIGURE 2. Rate* of reported hepatitis A, by race/ethnicity —
United States, 1990–2004
SOURCE: National Notifiable Diseases Surveillance System.



























FIGURE 3. Rate* of hepatitis A, by county — United States, 1987–1997 and 2004
SOURCE: National Notifiable Diseases Surveillance System.
* Per 100,000 population.
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of injection and noninjection drugs and among men who have
sex with men (MSM) (53–57), and up to 15% of nationally
reported cases occurred among persons reporting one or more
of these behaviors. Other potential sources of infection (e.g.,
international travel and recognized foodborne outbreaks) were
reported among 3%–6% of cases (52). For approximately 50%
of persons with hepatitis A, no source was identified for their
infection.
Communitywide Epidemics. During communitywide epi-
demics, infection was transmitted from person to person in
households and extended family settings. These epidemics
typically spread throughout the community, and no single
risk factor or risk group could be identified that accounted
for the majority of cases (31). Once initiated, epidemics often
persisted for 1–2 years and proved difficult to control (58,59).
Because children often have unrecognized or asymptomatic
infection, they played a key role in sustaining HAV transmis-
sion during these epidemics.
Vaccine Era
With the licensure of inactivated hepatitis A vaccines by the
Food and Drug Administration (FDA) during 1995–1996,
hepatitis A became a disease that was not only common but
also vaccine-preventable. Since 1996, and particularly since
ACIP’s 1999 recommendations for routine vaccination of
children living in areas with consistently elevated hepatitis A
rates, national hepatitis A rates have declined sharply (4). The
1999 recommendations called for routine vaccination of chil-
dren living in states and communities in which the average
hepatitis A rate during a baseline period of 1987–1997 was
>20 cases per 100,000 population, approximately twice the
national average, and for consideration of hepatitis A vaccina-
tion of children in those states and communities in which the
average rate during the baseline period was at least the
national average (3).
In 2004, a total of 5,683 cases (rate: 1.9 cases per 100,000
population) were reported, representing an estimated 24,000
acute clinical cases when underreporting is taken into account.
This rate was the lowest ever recorded and was 79% lower than
the previously recorded low in 1992 (5). This decline is
reflected in other fundamental shifts in hepatitis A epidemiology.
Variation by Age, Race/Ethnicity, and Region. Beginning
in the late 1990s, national age-specific rates declined more
rapidly among children than adults; as a result, in recent years,
rates have been similar among all age groups (Figure 1) (4).
Historic differences in rates among racial/ethnic populations
also have narrowed in the vaccine era. For example, recent
rates among American Indians and Alaska Natives represent a
99% decline compared with the prevaccine era and are now
approximately the same or lower than those of other racial/
ethnic populations (49). Rates among Hispanics also declined
87% during this period, from 20.6 cases per 100,000 popula-
tion during 1990–1997 to 2.7 per 100,000 in 2004, but
remain higher than those for non-Hispanics (Figure 2) (4,5).
Elimination of historic geographic differences in incidence rates
has also occurred, and since 2001, rates in states where vacci-
nation was recommended have been approximately equal to
the rest of the United States (5). In recent years, counties with
higher rates have varied from year to year and have been dis-
tributed throughout the country (Figure 3) (4).
Incidence declined sharply in states with historically consis-
tently elevated rates included in the 1999 ACIP recommen-
dations for routine vaccination of children. As a result, the
majority of hepatitis A cases during recent years have been
reported from states with historically low rates in which hepa-
titis A vaccination of children has not been widely imple-
mented (4). In addition, the narrowing or elimination of
national differences in age, race/ethnicity, and state-specific
rates can be attributed largely to changes that occurred in the
states in which routine hepatitis A vaccination of children was
recommended and implemented. In 2004, for example,
approximately two thirds of the nearly 6,000 cases were
reported from states without childhood vaccination recom-
mendations (60). The 2004 rate among all Hispanics in these
states remained four times higher than among non-Hispanics
and was seven times higher among Hispanic compared with
non-Hispanic children. The highest rate in any demographic
subgroup occurred among Hispanic children in states for
which routine hepatitis A vaccination of children is not
recommended (60).
Sources of Infection. In recent years, sexual or household
contact with a person with hepatitis A has been reported in a
smaller proportion of cases but continued to account for 13%
of cases during 2002–2004 (5). The proportion of persons
with hepatitis A reporting exposure to child care centers also
has declined to approximately 9% (5). The number of inter-
national travel-associated cases has remained approximately the
same, but as overall incidence has declined, the proportion of
cases attributable to this exposure has increased, accounting
for an average of 13% of cases during 2002–2004 (5). Dur-
ing this time, >25% of cases among children aged <15 years
could be attributed to international travel. Approximately 75%
of all travel-related cases were associated with travel to Mexico
or to Central or South America (5). Outbreaks among MSM
and users of illicit drugs also continue to occur (5,57).
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Groups at Increased Risk for Hepatitis A
Travelers
Persons from developed countries who travel to developing
countries are at substantial risk for acquiring hepatitis A (61).
Such persons include tourists, immigrants and their children
returning to their country of origin to visit friends or rela-
tives, military personnel, missionaries, and others who work
or study abroad in countries that have high or intermediate
endemicity of hepatitis A (Figure 4). Hepatitis A remains one
of the most common vaccine-preventable diseases acquired
during travel. One study estimated the risk among persons
who did not receive IG or vaccine before departure to be four
to 30 cases per 100,000 months of stay in developing coun-
tries (62). The risk might be higher among travelers staying in
areas with poor hygienic conditions, varies according to the
region and the length of stay, and appears to be increased even
among travelers who reported observing protective measures
and staying in urban areas or luxury hotels (CDC, unpub-
lished data, 2005). In the United States, children account for
approximately 50% of reported travel-related cases (5). In one
study of Hispanic children in San Diego with hepatitis A, two
thirds reported international travel (to Mexico) during the
incubation period; travel was the only exposure associated with
infection in a case-control study (63). Travelers who acquire
hepatitis A during their trips also might transmit to others on
their return.
MSM
Hepatitis A outbreaks among MSM have been reported fre-
quently. Cyclic outbreaks have occurred in urban areas in the
United States, Canada, Europe, and Australia and can occur
in the context of an outbreak in the larger community
(28,31,53,64–67). Seroprevalence surveys have not consis-
tently demonstrated an elevated prevalence of anti-HAV com-
pared with a similarly aged general population (68,69). Certain
studies have identified specific sex practices associated with
illness, whereas others have not demonstrated such associa-
tions (53,67,68). Since 1996, ACIP has recommended hepa-
titis A vaccination of MSM (2). Although precise data are
lacking, vaccine coverage appears to be low (53).
Users of Injection and Noninjection Drugs
During the preceeding 2 decades, outbreaks have been
reported with increasing frequency among users of injection
and noninjection drugs in Australia, Europe, and North
America (31,54,56,57,70). In the United States, outbreaks
have frequently involved users of injected and noninjected
methamphetamine, who have accounted for up to 48% of
reported cases during outbreaks (57,71). Cross-sectional
serologic surveys have demonstrated that injection-drug
users have a higher prevalence of anti-HAV than the general
U.S. population (68,72). Transmission among injection-drug
users probably occurs through both percutaneous and fecal-
oral routes (71). Since 1996, ACIP has recommended hepa-
titis A vaccination of users of illicit drugs, but vaccine
coverage data are not available (2).
Persons with Clotting-Factor
Disorders
During 1992–1993, outbreaks of
hepatitis A were reported in Europe
among persons with clotting-factor dis-
orders who had been administered
solvent-detergent–treated, “high-
purity” factor VIII concentrates that
presumably had been contaminated
from plasma donors incubating hepa-
titis A (73). In the United States, data
from one serologic study suggested that
persons with hemophilia might be at
increased risk for HAV infection (74).
HAV is resistant to solvent-detergent
treatment, and during 1995–1996, one
study identified six patients with
clotting-factor disorders who had hepa-
titis A after having been administered
solvent-detergent–treated factor VIII
FIGURE 4. Geographic distribution of hepatitis A endemicity, 2005*
* For multiple countries, estimates of prevalence of antibody to hepatitis A virus (anti-HAV), a marker
of previous HAV infection, are based on limited data and might not reflect current prevalence. In
addition, anti-HAV prevalence might vary within countries by subpopulation and locality. As used
on this map, the terms “high,” “medium,” and “low” endemicity reflect available evidence of how
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and factor IX concentrates (43). However, changes in viral
inactivation procedures, high hepatitis A vaccine coverage,
and improved donor screening have decreased the risk for HAV
transmission from clotting factors. During May 1998–July
2002, no new cases of HAV infection attributed to blood prod-
ucts were identified in an analysis of serosurveillance data from
140 participating hemophilia treatment centers (75).
Persons Working with Nonhuman Primates
Outbreaks of hepatitis A have been reported among per-
sons working with nonhuman primates that are susceptible to
HAV infection, including Old and New World species (76,77).
Primates that were infected were those that had been born in
the wild, not those born and raised in captivity.
Risk for Severe Adverse Consequences
of Hepatitis A Among Persons
with Chronic Liver Disease
Although not at increased risk for HAV infection, persons
with chronic liver disease are at increased risk for fulminant
hepatitis A (12,14,15). Death certificate data indicate a higher
prevalence of chronic liver disease among persons who died
of fulminant hepatitis A compared with persons who died of
other causes (10).
Risk for Hepatitis A in Other Groups
and Settings
Food-Service Establishments and Food
Handlers
Foodborne hepatitis A outbreaks are recognized relatively
infrequently in the United States. Outbreaks typically are
associated with contamination of food during preparation by
an HAV-infected food handler; a single infected food handler
can transmit HAV to dozens or even hundreds of persons
(34,36,37,78–81). However, the majority of food handlers
with hepatitis A do not transmit HAV. Food handlers are not
at increased risk for hepatitis A because of their occupation.
However, among the approximately 40,000 adults with hepa-
titis A reported during 1992–2000 for whom an occupation
was known, 8% were identified as food handlers, reflecting
the large number of persons employed in the food service
industry (34). Evaluating HAV-infected food handlers is a
common and labor-intensive task for public health depart-
ments. In a 1992 common-source outbreak involving 43 per-
sons, the estimated total medical and disease control cost was
approximately $800,000 (82).
Outbreaks associated with food, especially green onions and
other raw produce, that has been contaminated before reach-
ing a food-service establishment have been recognized
increasingly in recent years (29,30,83–88). Low attack rates
are common, and outbreaks often have been recognized in
association with a single restaurant in which no infected food
handler was identified on subsequent investigation (29,83,88).
Child Care Centers
Outbreaks among children attending child care centers and
persons employed at these centers have been recognized since
the 1970s, but their frequency has decreased as overall hepati-
tis A incidence among children has declined in recent years
(5,7,89). Because infection among children is typically mild
or asymptomatic, outbreaks often are identified only when
adult contacts (typically parents) become ill (7,90). Poor
hygiene among children who wear diapers and the handling
and changing of diapers by staff contribute to the spread of
HAV infection; outbreaks rarely occur in child care centers in
which care is provided only to children who are toilet trained.
Although child care centers might have been the source of
outbreaks of hepatitis A in certain communities, disease in
child care centers more commonly reflects extended transmis-
sion from the community. Despite the occurrence of outbreaks
when HAV is introduced into child care centers, results of
serologic surveys do not indicate a substantially increased
prevalence of HAV infection among staff at child care centers
compared with prevalence among control populations (91).
Health-Care Institutions
Nosocomial HAV transmission is rare. Outbreaks have occa-
sionally been observed in neonatal intensive-care units because
of infants acquiring infection from transfused blood and subse-
quently transmitting hepatitis A to other infants and staff
(18,92,93). Outbreaks of hepatitis A caused by transmission
from adult patients to health-care workers are typically associ-
ated with fecal incontinence, although the majority of hospital-
ized patients who have hepatitis A are admitted after onset of
jaundice, when they are beyond the point of peak infectivity
(94,95). Data from serologic surveys of health-care workers have
not indicated an increased prevalence of HAV infection in these
groups compared with that in control populations (96).
Institutions for Persons with Developmental
Disabilities
Historically, HAV infection was highly endemic in institutions
for persons with developmental disabilities (97). As fewer chil-
dren have been institutionalized and as conditions in institutions
have improved, the incidence and prevalence of HAV infection
have decreased, although outbreaks can occur in these settings.
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Schools
In the United States, the occurrence of cases of hepatitis A
in elementary or secondary schools typically reflects disease
acquisition in the community. Child-to-child disease trans-
mission in the school setting is uncommon; if multiple cases
occur among children at a school, the possibility of a com-
mon source of infection should be investigated (30,84).
Workers Exposed to Sewage
Data from serologic studies conducted outside the United
States indicate that workers who had been exposed to sewage
had a possible elevated risk for HAV infection; however, these
analyses did not control for other risk factors (e.g., socioeco-
nomic status) (98–100). In published reports of three sero-
logic surveys conducted among U.S. wastewater workers and
appropriate comparison populations, no substantial or con-
sistent increase in the prevalence of anti-HAV was identified
among wastewater workers (101–103). No work-related
instances of HAV transmission have been reported among
wastewater workers in the United States.
Strategy to Prevent and Control
Hepatitis A Through Vaccination
With the availability of hepatitis A vaccines beginning in
1995, hepatitis A became a disease that was not only com-
mon but also vaccine-preventable (104). Use of these highly
effective vaccines provided the opportunity to protect per-
sons from infection, reduce disease incidence by preventing
transmission, and ultimately eliminate indigenous HAV trans-
mission.
Soon after hepatitis A vaccines became available in the
United States, a strategy of routine vaccination of children
was recognized to have the potential to achieve a sustained
reduction in the overall incidence of hepatitis A by preventing
infection among persons in age groups that accounted for at
least one third of cases and eliminating a major source of
infection for others. However, hepatitis A vaccines could not
be readily incorporated into the routine infant and early child-
hood schedule because they were not licensed for children
aged <2 years. To overcome these logistical barriers to use of
hepatitis A vaccines among children, a novel vaccination strat-
egy was developed on the basis of distinct features of hepatitis
A epidemiology and experience gathered from demonstration
projects and other research and involving incremental imple-
mentation of routine childhood hepatitis A vaccination.
Initial recommendations primarily involved vaccination of
persons in populations at increased risk for hepatitis A and, as
the first step in the incremental strategy, of children living in
communities with the highest disease rates (2). Vaccination
of persons in groups at increased risk for hepatitis A (e.g.,
travelers) or its adverse outcomes (e.g., persons with chronic
liver disease) provided protection to these persons but had
little effect on national disease rates because the majority of
cases did not occur among persons in these groups. Although
routine vaccination of children living in communities with
the highest rates of disease was effective in reducing disease
rates in these communities, the impact on national disease
incidence was limited because the majority of nationally
reported cases occurred outside these communities.
A further step in the incremental implementation of routine
vaccination of children was possible because areas with consis-
tently elevated hepatitis A rates could be identified that con-
tributed the majority of cases to the national disease burden
(3). To date, the 1999 ACIP recommendations for routine vac-
cination of children living in these areas with consistently
elevated rates have been implemented primarily by voluntary
measures. The 2004 National Immunization Survey among
children aged 24–35 months indicated first-dose coverage of
approximately 54% in states for which vaccination is recom-
mended, 27% in states for which it is to be considered, and 2%
in the rest of the country (CDC, unpublished data, 2005).
Although limited information on trends is available, these cov-
erage estimates represent increases of 2%–3% compared with
the previous year (105). Coincident with implementation of
these recommendations, national disease incidence has declined
to historic lows, with the largest declines occurring in the age
groups and parts of the country for which vaccination is rec-
ommended (4). The majority of disease (and the highest inci-
dence) occurs in areas for which hepatitis A vaccination of
children has not been recommended previously. Examination
of historical incidence trends in these areas and theoretic mod-
els of incidence dynamics after introduction of a new vaccine
suggest that incidence might increase again, although to what
level is unknown (106).
A decade has passed since hepatitis A vaccines first became
available in the United States. Multiple considerations make
this an appropriate time to implement the final step in the
incremental strategy, thereby bringing hepatitis A vaccination
policy into line with that of other routinely recommended
childhood vaccines. First, hepatitis A vaccine became avail-
able for children aged 12–23 months in 2005, allowing for its
incorporation into the routine early childhood vaccination
schedule. Second, as disease rates equalize across regions of
the United States, questions remain regarding the validity and
ultimate sustainability of the interim limited strategy. Con-
tinuation of this policy in light of current hepatitis A epide-
miology means that vaccination of children is not presently
recommended for the areas with the highest overall and age-
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specific disease incidence. Nationwide hepatitis A vaccination
of children is likely to result in further narrowing of current
demographic disparities and in lower overall rates. Ultimately,
elimination of indigenous HAV transmission in the United
States is an attainable goal.
Prophylaxis Against Hepatitis A
Virus Infection
Immune Globulin
IG is a sterile preparation of concentrated antibodies
(immunoglobulins) made from pooled human plasma pro-
cessed by cold ethanol fractionation (107). In the United States,
only plasma that has tested negative for hepatitis B surface
antigen (HBsAg), antibody to human immunodeficiency
virus (HIV), and antibody to hepatitis C virus (HCV) is used
to produce IG. In addition, FDA requires that the process
used to produce IG include a viral inactivation step or that
final products test negative for HCV RNA by PCR. Anti-
HAV concentrations differ among IG lots, and slightly lower
concentrations have been observed over the preceding 30 years,
probably because of the decreasing prevalence of previous HAV
infection among plasma donors (108). However, no clinical
or epidemiologic evidence of decreased protection has been
observed.
IG provides protection against hepatitis A through passive
transfer of antibody. Both IG administered intramuscularly
(IM) and IG for intravenous administration (IGIV) contain
anti-HAV, but IG administered intramuscularly is the prod-
uct used for the prevention of HAV infection. No transmis-
sion of hepatitis B virus (HBV), HIV, HCV, or other viruses
has been reported from intramuscular IG (109,110). The con-
centrations of IgG anti-HAV achieved after administration of
IG intramuscularly are below the level of detection of the
majority of commercially available diagnostic tests (111).
When administered for preexposure prophylaxis, 1 dose of
0.02 mL/kg IM confers protection for <3 months, and 1 dose
of 0.06 mL/kg IM confers protection for 3–5 months
(Table 1). When administered within 2 weeks after an expo-
sure to HAV (0.02 mL/kg IM), IG is 80%–90% effective in
preventing hepatitis A. Efficacy is greatest when IG is admin-
istered early in the incubation period; when administered later
in the incubation period, IG might only attenuate the clini-
cal expression of HAV infection (112).
IG is available in single-use (2 mL) and multidose (10 mL)
vials. Preparations are formulated without a preservative. For
administration of IG, an appropriate muscle mass (i.e., the
deltoid or gluteal muscle) should be chosen into which a sub-
stantial volume can be injected, using a needle length appro-
priate for the person’s age and size. If a gluteal muscle is used,
the central region of the buttock should be avoided; only the
upper outer quadrant should be used, and the needle should
be directed anteriorly to minimize the possibility of injury to
the sciatic nerve (113).
Serious adverse events from IG are rare. Anaphylaxis has
been reported after repeated administration to persons with
known immunoglobulin A (IgA) deficiency; thus, IG should
not be administered to these persons (114). Pregnancy or lac-
tation is not a contraindication to IG administration.
IG does not interfere with the immune response to oral
poliovirus vaccine or yellow fever vaccine, or, in general, to
inactivated vaccines. However, IG can interfere with the
response to other live, attenuated vaccines (e.g., measles,
mumps, and rubella [MMR] vaccine and varicella vaccine)
when administered either as individual or combination vac-
cines. Administration of MMR should be delayed for >3
months and varicella vaccine for >5 months after administra-
tion of IG for hepatitis A prophylaxis. IG should not be ad-
ministered <2 weeks after administration of MMR or <3 weeks
after varicella vaccine unless the benefits of IG administration
exceed the benefits of vaccination (113,115). If IG is admin-
istered <2 weeks after administration of MMR or <3 weeks
after administration of varicella vaccine, the person should be
revaccinated, but not sooner than 3 months after IG adminis-
tration for MMR or 5 months for varicella vaccine (113).
Hepatitis A Vaccine
Inactivated and attenuated hepatitis A vaccines have been
developed and evaluated in human clinical trials and in non-
human primate models of HAV infection (116); however, only
vaccines made from inactivated HAV have been evaluated for
efficacy in controlled clinical trials (117–119). The vaccines
containing HAV antigen that are currently licensed in the
United States are the single-antigen vaccines HAVRIX®
(manufactured by GlaxoSmithKline, Rixensart, Belgium) and
VAQTA® (manufactured by Merck & Co., Inc., Whitehouse
Station, New Jersey) and the combination vaccine TWINRIX®
(containing both HAV and HBV antigens; manufactured by
GlaxoSmithKline). All are inactivated vaccines.
TABLE 1. Recommended doses of immune globulin (IG) for
hepatitis A preexposure and postexposure prophylaxis
Setting Duration of coverage Dose (mL/kg)*
Preexposure Short-term (1–2 mos) 0.02
 Long-term (3–5 mos) 0.06†
Postexposure 0.02
* IG should be administered by intramuscular injection into either the
deltoid or gluteal muscle. For children aged <24 months, IG can be
administered in the anterolateral thigh muscle.
†Repeat every 5 months if continued exposure to hepatitis A virus occurs.
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Preparation
Inactivated hepatitis A vaccines are prepared by methods
similar to those used for inactivated poliovirus vaccine
(120,121). Cell-culture–adapted virus is propagated in
human fibroblasts, purified from cell lysates by ultrafiltration
and exclusion gel chromatography or other methods, forma-
lin inactivated, and adsorbed to an aluminum hydroxide
adjuvant; 2-phenoxyethanol is used as a preservative for
HAVRIX and TWINRIX, and VAQTA is formulated with-
out a preservative. For HAVRIX and TWINRIX, the antigen
content of the final aqueous preparation is determined by
reactivity in a quantitative immunoassay for HAV antigen, and
final vaccine potency (per dose) is expressed as enzyme-linked
immunosorbent assay (ELISA) units (EL.U.). For VAQTA, the
antigen content is expressed as units (U) of HAV antigen.
Vaccine Storage and Shipment
Hepatitis A vaccine should be stored and shipped at tem-
peratures ranging from 35.6°F–46.4°F (2°C–8°C) and should
not be frozen. However, the reactogenicity and immunoge-
nicity of HAVRIX after storage at 98.6°F (37°C) for 1 week
and the stability profile of VAQTA when stored at this tem-
perature for >12 months do not differ from those of vaccines
stored at the recommended temperature (122; Merck & Co.,
Inc., unpublished data, 1996).
Route of Administration, Vaccination
Schedule, and Dosage
The vaccine should be administered intramuscularly into
the deltoid muscle. A needle length appropriate for the person’s
age and size should be used (113).
VAQTA is licensed in two formulations, which differ
according to the person’s age. Persons aged 12 months–18
years should receive 25 U per dose in a 2-dose schedule; per-
sons aged >18 years should receive 50 U per dose in a 2-dose
schedule (Table 2).
HAVRIX is available in two formulations, which differ
according to the person’s age: for persons aged 12 months–18
years, 720 EL.U. per dose in a 2-dose schedule; and for per-
sons aged >18 years, 1,440 EL.U. per dose in a 2-dose sched-
ule (Table 3). A pediatric formulation of 360 EL.U. per dose
administered in a 3-dose schedule is no longer available.
TWINRIX is licensed for use in persons aged >18 years.
TWINRIX is a combined hepatitis A and hepatitis B vaccine
containing 720 EL.U. of hepatitis A antigen (half of the
HAVRIX adult dose) and 20 mcg of recombinant hepatitis B
surface antigen protein (the same as the ENGERIX-B adult
dose) (Table 4). Primary immunization consists of 3 doses,
administered on a 0-, 1-, and 6-month schedule, the same
schedule as that commonly used for single-antigen hepatitis
B vaccine. TWINRIX contains aluminum phosphate and alu-
minum hydroxide as adjuvant and 2-phenoxyethanol as a pre-
servative. After 3 doses of TWINRIX, antibody responses to
both antigens are equivalent to responses seen after the single-
antigen vaccines are administered separately on standard sched-
ules (123,124).
Vaccine Performance
Detection of Anti-HAV After Vaccination. Concentrations
of antibody achieved after passive transfer by IG or active
induction by vaccination are 10- to 100-fold lower than those
produced after natural infection and can be below the level of
detection of certain commercially available diagnostic assays
(111). To measure lower levels of antibody, more sensitive im-
munoassays were developed for immunogenicity studies that
correlate more closely with neutralizing antibody assays (111).
Anti-HAV concentrations are measured in comparison with a
World Health Organization reference immunoglobulin reagent
and are expressed as milli-International Units per milliliter
(mIU/mL). The lower limits of detection have typically been
approximately 100 mIU/mL by unmodified commercially avail-
able assays and 10 mIU/mL by more sensitive assays. A positive
anti-HAV result by a standard assay indicates protection. How-
ever, after vaccination, persons who are anti-HAV negative by
TABLE 4. Licensed dosages of TWINRIX®*
Vaccine Dose (hepatitis A/ Vol. No. Schedule
recipient’s age hepatitis B) (mL) doses (mos)†
>18 yrs 720 EL.U.§/20 µg 1.0 3 0, 1, 6
* Combined hepatitis A and hepatitis B vaccine, GlaxoSmithKline
(Rixensart, Belgium).
†0 months represents timing of initial dose; subsequent numbers
represent months after the initial dose.
§Enzyme-linked immunosorbent assay units.
TABLE 2. Licensed dosages of VAQTA®*
Dose Vol. No. Schedule
Vaccine recipient’s age (U)† (mL) doses (mos)§
12 mos–18 yrs 25 0.5 2 0, 6–18
>19 yrs 50 1.0 2 0, 6–18
* Hepatitis A vaccine, inactivated, Merck & Co., Inc. (Whitehouse Station, New
Jersey).
†Units.
§0 months represents timing of initial dose; subsequent numbers
represent months after the initial dose.
TABLE 3. Licensed dosages of HAVRIX®*
Dose Vol. No. Schedule
Vaccine recipient’s age (EL.U.)† (mL) doses (mos)§
12 mos–18 yrs 720 0.5 2 0, 6–12
>19 yrs 1,440 1.0 2 0, 6–12
* Hepatitis A vaccine, inactivated, GlaxoSmithKline (Rixensart, Belgium).
†Enzyme-linked immunosorbent assay units.
§0 months represents timing of initial dose; subsequent numbers
represent months after the initial dose.
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standard assays might nevertheless have protective levels of
antibody.
The absolute lower limit of anti-HAV required to prevent
HAV infection has not been defined. In vitro studies using
cell-culture-derived virus indicate that low levels of antibody
(e.g., <20 mIU/mL) can be neutralizing (125). Clinical stud-
ies have yielded limited data from which a minimum protec-
tive antibody level can be derived because vaccine-induced
levels of antibody have been high and few infections have been
detected among vaccinated persons. Experimental studies in
chimpanzees indicate that low levels of passively transferred
antibody (<10 mIU/mL) obtained from immunized persons
do not protect against infection but do prevent clinical hepa-
titis and virus shedding (126). To define a protective anti-
body response, clinical studies conducted with HAVRIX have
used levels >20 mIU/mL, or >33 mIU/mL in more recent
studies, as measured with modified enzyme immunoassays,
and studies conducted with VAQTA have used levels >10
mIU/mL as measured with a modified radioimmunoassay
(127,128).
Immunogenicity in Adults. All licensed vaccines are highly
immunogenic in persons aged >18 years when administered
according to the recommended schedules (128–130). Protec-
tive antibody levels were identified in 94%–100% of adults
1 month after the first dose. After the second dose, all persons
had protective levels of antibody, with high geometric mean
antibody concentrations (GMCs).
Limited data are available regarding the timing of the appear-
ance of neutralizing antibody. Among a sample of vaccinated
persons, 54%–62% were positive for neutralizing antibody
14 days after the first dose, and 94%–100% were positive at
1 month (128; GlaxoSmithKline, unpublished data, 1994).
Immunogenicity in Children and Adolescents. Both vac-
cines are highly immunogenic when administered to children
and adolescents according to multiple schedules; 97%–100%
of persons aged 2–18 years had protective levels of antibody
1 month after receiving the first dose, and 100% had protec-
tive levels 1 month after the second dose, with high GMCs
(128–133). Children with Down syndrome responded to vac-
cination as well as other children and had similar levels of
protective antibody (134).
Immunogenicity in Infants. Available data indicate that
inactivated hepatitis A vaccines are immunogenic in children
aged <2 years who do not have passively acquired maternal
antibody. All such infants administered hepatitis A vaccine
subsequently had protective antibody levels, with the final
GMCs varying depending on the dosage and schedule
(135–139). Infants with passively acquired maternal antibody
had reduced GMCs after vaccination (see Factors Associated
with Reduced Immunogenicity) (135,136).
IgM Anti-HAV After Vaccination. Hepatitis A vaccina-
tion can induce IgM anti-HAV that is detectable by standard
assays, particularly if the test is conducted soon after vaccina-
tion. IgM anti-HAV has been detected 2–3 weeks after
administration of one dose of vaccine in 8%–20% of adults
(140; CDC, unpublished data, 1995).
Efficacy. The efficacy of HAVRIX was evaluated in a double-
blind, controlled, randomized clinical trial conducted in Thai-
land among approximately 40,000 children aged 1–16 years living
in villages that had high rates of hepatitis A (117). After 2 doses
of vaccine (360 EL.U. per dose) administered 1 month apart, the
efficacy of vaccine in protecting against clinical hepatitis A was
94% (95% confidence interval [CI] = 79%–99%). A double-
blind, placebo-controlled, randomized clinical trial using VAQTA
was conducted among approximately 1,000 children aged 2–16
years living in a New York community that had a high rate of
hepatitis A (118). The protective efficacy against clinical hepati-
tis A was 100% (lower bound of the 95% CI = 87%) after
administration of 1 dose (25 U) of vaccine.
Efficacy After Exposure. Studies of chimpanzees indicate
that hepatitis A vaccine can prevent HAV infection if admin-
istered shortly after exposure (141). Because the incubation
period of hepatitis A can be 50 days, the fact that during a
clinical efficacy trial, no cases of hepatitis A occurred in vac-
cine recipients beginning 17 days after vaccination also sug-
gests a possible postexposure effect (118,142). In a limited
randomized trial, investigators determined that hepatitis A
vaccine was 79% efficacious in preventing IgM anti-HAV
positivity after household exposure to hepatitis A compared
with no treatment. However, the CI was extremely wide
(7%–95%), and investigators did not assess the efficacy of the
vaccine compared with IG (143). Results of an appropriately
designed clinical trial comparing the postexposure efficacy of
vaccine with that of IG are needed to determine if hepatitis A
vaccine without IG can be recommended to prevent hepatitis
A after exposure (144).
Effectiveness in Populations. The effectiveness of hepati-
tis A vaccine in populations has been studied in demonstra-
tion projects and by analysis of surveillance and vaccine
coverage data. The earliest such studies focused on communi-
ties with the historically highest hepatitis A rates, such as Alaska
Native and American Indian communities. Demonstration
projects conducted soon after hepatitis A vaccines became
available indicated that routine vaccination of children living
in these communities was feasible and that when relatively
high vaccination coverage was achieved and sustained,
ongoing epidemics were interrupted and a reduction in
disease incidence was sustained (145–147). For example, a
1992–1993 communitywide epidemic among Alaska Natives
in one rural area ended within 4–8 weeks of vaccinating
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approximately 80% of children and young adults (146).
After publication in 1996 of ACIP recommendations for rou-
tine vaccination of children in these areas, surveys indicated
that vaccine coverage among preschool- and school-aged
American Indian and Alaska Native children was 50%–80%,
suggesting that recommendations were being implemented
(2,49). By 2000, hepatitis A incidence among American
Indians and Alaska Natives had declined 97% compared with
the beginning of the decade and was lower than the overall U.S.
rate (49). These low rates have been sustained in subsequent
years; the 2004 rate of 0.1 case per 100,000 population among
American Indian and Alaska Natives was the lowest of any racial/
ethnic population (5).
Results of a demonstration project in Butte County, Califor-
nia, provided evidence that considerable reductions in overall
incidence also could be achieved in populations with consis-
tently elevated hepatitis A rates with a program of ongoing rou-
tine vaccination of children that achieved fairly modest coverage
(148). During the 6-year project, 66% of the approximately
45,000 eligible children aged >2 years received >1 dose of hepa-
titis A vaccine. The number of reported cases declined 94%,
and the four cases reported in 2000 during the last year of the
project was the lowest number ever reported in the county since
hepatitis surveillance began in 1966.
The most comprehensive indication of the performance of
hepatitis A vaccines in populations is derived from analysis of
trends in hepatitis A incidence after publication of ACIP’s 1999
recommendations for routine vaccination of children living in
17 states with consistently elevated hepatitis A rates. The 2003
rate (2.5 cases per 100,000 population) in these states repre-
sented a decline of approximately 88% compared with the
average rate (21.1 cases per 100,000 population) during the
baseline prevaccine period on which the recommendations were
based of (4). Rates among regions with and without statewide
recommendations for routine vaccination of children are now
approximately equal (Figure 5). Compared with 1990–1997,
rates declined most dramatically among children aged 2–18
years, and the proportion of cases among children declined from
35% to 19%. Because hepatitis A incidence has been cyclic in
the United States, the precise contribution of vaccination of
children to the observed decline in rates has been difficult to
quantify. Modeling studies suggested that during 1995–2001,
an estimated 97,800 hepatitis A cases were averted because of
the direct effects of immunization and herd immunity, includ-
ing 39% of potential cases in 2001 (149).
Available information concerning vaccine use indicates that
the observed declines in rates among children appear to have
been achieved with modest levels of vaccine coverage, sug-
gesting a strong herd immunity effect (105,150). Declines in
rates among adults also suggest that vaccination of children
might have reduced transmission in other age groups through
herd immunity. Similar findings have been reported from other
countries (e.g., Israel and parts of Spain) in which routine
hepatitis A vaccination of infants or children has been imple-
mented (151,152). Results of modeling the relationship
between hepatitis A incidence and vaccine coverage have also
indicated a strong herd immunity effect, accounting for more
than one third of the estimated number of cases prevented by
vaccination (149).
Interest has been expressed regarding use of hepatitis A vac-
cine to interrupt ongoing communitywide epidemics by vac-
cinating children in these populations, but the strategy has
proved difficult to implement. Typically, first-dose coverage
was low (20%–45%), and the impact of vaccination always
was limited to vaccinated age groups that did not represent the
majority of cases (59). Efforts are probably better directed
towards sustained routine vaccination of children to maintain
high levels of immunity and prevent future epidemics.
Long-Term Protection. All 31 adults who received 3 doses
of HAVRIX (720 EL.U. per dose at 0-, 1-, and 6-month
intervals) had anti-HAV levels >15 mIU/mL 12 years after
the initial dose (153). Ten years after vaccination, all 307 adults
administered 2 doses of 1,440 EL.U. of HAVRIX had anti-
HAV levels >20 mIU/mL (154). Protective levels of anti-HAV
were still observed in 544 (99%) of 549 children evaluated
5–6 years after receiving VAQTA (155). A recent review con-
cluded that estimates of antibody persistence derived from
kinetic models of antibody decline indicate that protective
levels of anti-HAV could be present for >25 years in adults
and >14–20 years in children (156). Whether other mecha-
FIGURE 5. Rate* of hepatitis A, by region, recommendation
for childhood vaccination, and year — 1990–2004
SOURCE: National Notifiable Diseases Surveillance System.
* Per 100,000 population.
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nisms (e.g., cellular memory) also contribute to long-term
protection is unknown. Surveillance data and population-based
studies are being used to monitor the long-term protective
efficacy of hepatitis A vaccine and to determine the possible
need for a booster dose. In the longest such follow-up study
reported to date, no cases of hepatitis A have been detected
among children studied for 9 years after vaccination (157).
Vaccination Schedules. Results of multiple studies indi-
cate that, among adults administered hepatitis A vaccine
according to a schedule that mixed the two currently licensed
vaccines, the proportion that subsequently had protective
antibody levels did not differ from that of adults vaccinated
according to the licensed schedules, and final GMCs were
high (158,159). Although using the vaccines according to the
licensed schedule is preferable, on the basis of the similar
immunogenicity of both vaccines in adults and children, these
data indicate that the two brands of hepatitis A vaccine can be
considered interchangeable.
Limited data are available regarding response to a delayed
second vaccine dose. In one study, 85 (97%) of 88 persons
aged >18 years who had received 1 dose of VAQTA (50 U)
had anti-HAV levels >10 mIU/mL 18 months later. None
reported a history of hepatitis A, and all responded to a sec-
ond dose. Final GMCs were not different compared with per-
sons vaccinated according to a 0-, 6-month schedule (160).
In another study, 132 (84%) of 156 persons aged 1 month–
64 years who had responded to 1 dose of HAVRIX (720 EL.U.
for children aged <18 years; 1,440 EL.U. for adults) had anti-
HAV levels >20 mIU/mL a mean of 27 months later. None of
these persons reported a history of hepatitis A. All but one of
these persons responded to a second dose, with a substantial
rise in antibody levels (161). In a third study, 18 (72%) of 25
adults who had received 1 dose of HAVRIX 4–8 years previ-
ously had anti-HAV levels >10 mIU/mL, and all 25
responded to a second dose of vaccine with a substantial
increase in anti-HAV levels (162).
Factors Associated with Reduced Immunogenicity. The
presence of passively acquired anti-HAV at the time of vacci-
nation appears to diminish the immune response. Adminis-
tration of IG concurrently with the first dose of hepatitis A
vaccine did not decrease the proportion of adults who subse-
quently had protective levels of antibody compared with adults
who had been administered hepatitis A vaccine alone, but
GMCs of adults who received IG were substantially lower
1 month after completion of the vaccine series than GMCs of
adults who had been administered hepatitis A vaccine alone
(163,164). However, their antibody levels were >100-fold
higher than levels considered to be protective, suggesting that
the reduced immunogenicity of hepatitis A vaccine that
occurs with concurrent administration of IG is not clinically
significant in the short term. The effect of reduced GMCs on
long-term protection is unknown.
Reduced vaccine immunogenicity also has been observed
in infants who had passively acquired antibody because of
previous maternal HAV infection and were administered hepa-
titis A vaccine according to a number of different schedules
(135–137). In the majority of studies, all infants subsequently
had protective levels of antibody, but the final GMCs were
approximately one third to one tenth those of infants born to
anti-HAV–negative mothers and vaccinated according to the
same schedule. Infants with passively acquired antibody who
receive hepatitis A vaccine had substantially lower concentra-
tions of anti-HAV 6 years later compared with vaccinated
infants with no passively acquired antibody (165). Despite
lower antibody levels after the primary series, the majority of
infants with passively acquired antibody had an anamnestic
response to a booster dose 1–6 years later (136,165,166). Pas-
sively acquired antibody declines to undetectable levels in the
majority of infants by age 1 year (167,168). Hepatitis A vac-
cine is highly immunogenic for children who begin vaccina-
tion at age >1 year, regardless of maternal anti-HAV status
(136,168).
Hepatitis A vaccine using a standard dose and schedule is
immunogenic for children and adults with HIV infection.
Those with higher CD4 counts (>300 cells/mm3) respond
nearly as well as persons who are not immunocompromised,
but adults with lower CD4 counts are less likely to acquire
protective levels of antibody. Protective levels of antibody
developed after vaccination in 61%–87% of HIV-infected
adults (169–171) and in 100% of 32 HIV-infected children
(172). Lower CD4 cell count at the time of vaccination, but
not the CD4 cell count nadir, was associated with lack of
response, suggesting that immunologic reconstitution with
highly active antiretroviral therapy might restore the ability to
respond to vaccination (173).
Vaccination of children or adults with chronic liver disease of
viral or nonviral etiology produced seroprotection rates similar
to those observed in healthy adults. However, final antibody
levels were substantially lower for each group of chronic liver
disease patients than for healthy adults (174–179). Immuno-
genicity in liver transplant recipients has varied among studies.
In one study, none of the eight patients who had received a liver
transplant responded to hepatitis A vaccination; in another study,
only six (26%) of 23 liver transplant recipients responded
(176,179). However, hepatitis A vaccine was immunogenic for
liver transplant patients in another study, with 38 (97%)
responding to a standard dose and schedule (180). Only 28
(72%) of 39 kidney transplant recipients in this study subse-
quently had protective levels of antibody. A follow-up study
indicated that antibody levels might decline more rapidly for
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both liver and kidney transplant recipients compared with typical
rates of decline for healthy patients (181).
Limited data indicate that age might reduce the immuno-
genicity of hepatitis A vaccine. In certain studies, the propor-
tion of persons aged >40 years who had protective antibody
levels was similar to that of persons aged <40 years, but final
antibody levels were lower in the older age group (130,182–
184). Additional factors associated with decreased immuno-
genicity to other vaccines (e.g., smoking and obesity) have
not been evaluated for the currently licensed formulations of
hepatitis A vaccine. No data are available pertaining to
response rates to revaccination among persons who do not
respond to the primary vaccine series.
Simultaneous Administration with Other Vaccines. Lim-
ited data from studies conducted among adults indicate that
simultaneous administration of hepatitis A vaccine with diph-
theria, poliovirus (oral and inactivated), tetanus, typhoid (both
oral and IM), cholera, Japanese encephalitis, rabies, or yellow
fever vaccines does not decrease the immune response to
either vaccine or increase the frequency of reported adverse
events (185–187). Studies indicating that hepatitis B vaccine
can be administered simultaneously with hepatitis A vaccine
without affecting either vaccine’s immunogenicity or increas-
ing the frequency of adverse events led to the licensure of
TWINRIX (188). Studies conducted among infants and
young children aged <18 months have demonstrated that
simultaneous administration of hepatitis A vaccine with
diphtheria-tetanus-acellular pertussis (DTaP), Haemophilus
influenzae type b (Hib), hepatitis B, MMR, or inactivated
poliovirus vaccines does not affect the immunogenicity and
reactogenicity of these vaccines (136,189–192).
Side Effects and Adverse Events
Data on adverse events are derived from prelicensure clini-
cal studies worldwide, reports following licensure of HAVRIX
in Europe and Asia, other postlicensure studies, and reports
to the national Vaccine Adverse Events Reporting System
(VAERS) following licensure of HAVRIX and VAQTA in the
United States.
Local Reactions
Approximately 50,000 persons were administered HAVRIX
in prelicensure clinical studies (190). No serious adverse events
were attributed definitively to hepatitis A vaccine. Among
adults, the most frequently reported side effects occurring
<3 days after the 1,440-EL.U. dose were soreness at the injec-
tion site (56%), headache (14%), and malaise (7%). In clini-
cal studies among children, the most frequently reported side
effects were soreness at the injection site (15%), feeding prob-
lems (8%), headache (4%), and injection-site induration (4%).
The frequency of side effects after administration of TWINRIX
was similar to those reported when the two single-antigen
vaccines were administered (123,124,191).
Approximately 10,000 persons were administered VAQTA
in prelicensure clinical studies, and no serious adverse events
were reported among participants (192). Among adults, the
most frequent side effects that occurred <5 days after vaccina-
tion included tenderness (53%), pain (51%), and warmth
(17%) at the injection site and headache (16%). Among chil-
dren, the most common side effects reported were pain (19%),
tenderness (17%), and warmth (9%) at the injection site. In
one placebo-controlled trial among children, adverse reactions
among vaccine recipients did not differ substantially from those
that occurred among persons who received placebo (118).
Serious Adverse Events
An estimated 1.3 million persons in Europe and Asia were
vaccinated with HAVRIX before the vaccine’s licensure in the
United States in 1995. Reports of serious adverse events, with-
out regard to causality, received by the vaccine manufacturer
included anaphylaxis, Guillain-Barré syndrome, brachial
plexus neuropathy, transverse myelitis, multiple sclerosis,
encephalopathy, and erythema multiforme (SmithKline
Beecham Biologicals, unpublished data, 1995). The majority
of these events occurred among adults, and approximately one
third occurred among persons receiving other vaccines con-
currently. For serious adverse events for which background
incidence data can be estimated (e.g., Guillain-Barré syndrome
and brachial plexus neuropathy), rates for vaccine recipients
were not higher than would be expected for an unvaccinated
population (CDC, unpublished data, 1995).
No serious adverse events were reported for approximately
40,000 children who were administered the 360-EL.U. dose
of HAVRIX in the protective efficacy study (117). In a
postlicensure study of 11,417 children and 25,023 adults who
were administered VAQTA, no serious adverse events occurred
that were considered to be associated with administration of
vaccine (Merck & Co., Inc., unpublished data, 2005). A pub-
lished postlicensure evaluation of safety among 2,000 child
and adult recipients identified no serious adverse events asso-
ciated with VAQTA (193).
Since vaccine licensure in 1995, approximately 188 million
doses of hepatitis A vaccine have been sold worldwide, including
50 million doses in the United States (GlaxoSmithKline,
unpublished data, 2005; Merck & Co., Inc., unpublished data,
2005). During January 1995–October 2005, VAERS received
6,136 reports of adverse events among persons who received
Vol. 55 / RR-7 Recommendations and Reports 15
hepatitis A vaccine, with or without other vaccines (FDA,
unpublished data, 2005). The most common events were fever,
injection-site reactions, rash, and headache. The 871 reports of
serious adverse events included reports of Guillain-Barré syn-
drome, transaminitis, and idiopathic thrombocytopenic pur-
pura, which had been described previously in a published safety
review, and seizures among children (194). The relation, if any,
between the vaccine and reported serious events was not clear.
In the original safety review, reported adverse events were simi-
lar for VAQTA and HAVRIX (194). The safety of the vaccine
will continue to be assessed through ongoing monitoring of
data from VAERS and other surveillance systems.
Any adverse event suspected to be associated with hepatitis
A vaccination should be reported to VAERS. Information on
how to report adverse events is available at http://www.fda.gov/
cber/vaers/vaers.htm; forms for this purpose can be obtained
at telephone 800-822-7967.
Contraindications and Precautions
Hepatitis A vaccine should not be administered to persons
with a history of a severe allergic reaction to a previous dose of
hepatitis A vaccine or to a vaccine component. The safety of
hepatitis A vaccination during pregnancy has not been deter-
mined; however, because hepatitis A vaccine is produced from
inactivated HAV, the theoretic risk to the developing fetus is
expected to be low. The risk associated with vaccination should
be weighed against the risk for hepatitis A in pregnant women
who might be at high risk for exposure to HAV. Because hepa-
titis A vaccine is inactivated, no special precautions need to be
taken when vaccinating immunocompromised persons.
Prevaccination Serologic Testing
for Susceptibility
Antibody production in response to HAV infection results
in lifelong immunity to hepatitis A and, presumably, to HAV
infection. Vaccination of a person who is immune because of
previous infection does not increase the risk for adverse events.
In populations that have expected high rates of previous HAV
infection, prevaccination testing may be considered to reduce
costs by not vaccinating persons who are already immune.
Testing of children is not indicated because of their
expected low prevalence of infection. For adults, the decision
to test should be based on 1) the expected prevalence of
immunity, 2) the cost of vaccination compared with the cost
of serologic testing (including the cost of an additional visit),
and 3) the likelihood that testing will not interfere with ini-
tiation of vaccination. For example, if the cost of screening
(including laboratory and office visits) is one third the cost of
the vaccine series, then screening potential recipients in popu-
lations for which the prevalence of infection is likely to be
>33% should be cost-effective (195).
Persons for whom prevaccination testing will likely be most
cost-effective include adults who were either born in or lived
for extensive periods in geographic areas that have a high or
intermediate endemicity of hepatitis A (Figure 4); older adoles-
cents and adults in certain population groups (i.e., American
Indians, Alaska Natives, and Hispanics); and adults in certain
groups that have a high prevalence of infection (e.g., injection-
drug users). In addition, prevalence might be high enough
among all older adults to warrant prevaccination testing. Over-
all anti-HAV prevalence among persons aged >40 years, deter-
mined by NHANES-III testing, was >33% (50). Therefore, if
the cost of screening is one third the cost of the vaccine series,
prevaccination testing of any person aged >40 years would likely
be cost-effective. Commercially available tests for total anti-HAV
should be used for prevaccination testing.
Postvaccination Testing for Serologic
Response
Postvaccination testing is not indicated because of the high
rate of vaccine response among adults and children. In addi-
tion, not all testing methods approved for routine diagnostic
use in the United States have the sensitivity to detect low anti-
HAV concentrations after vaccination.
Cost-Effectiveness of Hepatitis A
Vaccination of Children
The cost-effectiveness of nationwide routine hepatitis A
vaccination was evaluated in an analysis that used a Markov
model to follow a single U.S. birth cohort of approximately
4 million persons from birth in 2005 through age 95 years or
death. Compared with no childhood vaccination, routine vac-
cination at age 1 year would result in 183,806 fewer infec-
tions and 32 fewer deaths in each cohort (CDC, unpublished
data, 2005). The cost-effectiveness ratio was estimated at
$173,000 per life year gained and $24,000 per quality-
adjusted life year (QALY) gained. Compared with 2003 vac-
cine coverage levels, the incremental cost-effectiveness ratio
of routine nationwide vaccination at age 1 year was $73,000
per QALY gained. When out-of-cohort herd immunity was
taken into account, vaccination at age 1 year yielded a societal
cost of $1,000 per QALY gained. Another economic analysis
that included the estimated reduction in secondary cases
among household contacts of infected children yielded simi-
lar results (196).
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Recommendations for Use
of Hepatitis A Vaccine
and Immune Globulin
Preexposure Protection Against HAV
Infection
The following recommendations for hepatitis A vaccina-
tion are intended to further reduce hepatitis A morbidity and
mortality in the United States and make possible consider-
ation of eventual elimination of HAV transmission. Hepatitis
A vaccination is recommended routinely for children, for
persons who are at increased risk for infection, and for any
person wishing to obtain immunity.
Children
• All children should receive hepatitis A vaccine at age
1 year (i.e., 12–23 months). Vaccination should be com-
pleted according to the licensed schedules (Tables 2 and
3) and integrated into the routine childhood vaccination
schedule. Children who are not vaccinated by age 2 years
can be vaccinated at subsequent visits.
• States, counties, and communities with existing hepatitis
A vaccination programs for children aged 2–18 years are
encouraged to maintain these programs. In these areas,
new efforts focused on routine vaccination of children
aged 1 year should enhance, not replace, ongoing
programs directed at a broader population of children.
• In areas without existing hepatitis A vaccination programs,
catch-up vaccination of unvaccinated children aged 2–18
years can be considered. Such programs might especially
be warranted in the context of increasing incidence or
ongoing outbreaks among children or adolescents.
Persons At Increased Risk for HAV Infection
Persons Traveling to or Working in Countries That Have
High or Intermediate Endemicity of Infection
All susceptible persons traveling to or working in countries
that have high or intermediate hepatitis A endemicity
(Figure 4) should be vaccinated or receive IG before depar-
ture (Tables 1–4). Hepatitis A vaccination at the age-
appropriate dose is preferred (Tables 2–4). Prevaccination
testing should be considered for older travelers or for younger
persons in certain population groups (see Prevaccination
Serologic Testing for Susceptibility).
Travelers to Australia, Canada, western Europe, Japan, or
New Zealand (i.e., countries in which endemicity is low) are
at no greater risk for infection than persons in the United
States. Data are not available regarding the risk for hepatitis A
for persons traveling to certain areas of the Caribbean, although
vaccine or IG should be considered if travel to areas that have
questionable sanitation is anticipated.
The first dose of hepatitis A vaccine should be administered
as soon as travel is considered. Travelers who are administered
vaccine can be assumed to be protected within 4 weeks after
receiving the first vaccine dose. Persons administered single-
antigen hepatitis A vaccine often will have detectable anti-
HAV by 2 weeks after the first vaccine dose; the proportion of
persons who will have detectable anti-HAV at 2 weeks might
be lower when lower vaccine dosages are used (e.g., in
TWINRIX). However, no data are available regarding the risk
for hepatitis A among persons vaccinated 2–4 weeks before
departure. Because protection might not be complete until
4 weeks after vaccination, for optimal protection, persons trav-
eling to an area in which risk is high <4 weeks after the initial
dose also may be administered IG (0.02 mL/kg), but at a dif-
ferent anatomic injection site. Travelers departing in <4 weeks
who do not or cannot receive IG should nonetheless receive
hepatitis A vaccine and be informed that they might not be
optimally protected from acquiring hepatitis A in the imme-
diate future (i.e., subsequent 2–4 weeks). Completion of the
vaccine series according to the licensed schedule (Tables 2–4)
is necessary for long-term protection.
Travelers who are allergic to a vaccine component or who
elect not to receive vaccine should receive a single dose of
IG (0.02 mL/kg), which provides effective protection
against hepatitis A for up to 3 months (Table 1). Travelers
whose travel period is >2 months should be administered IG
at 0.06 mL/kg; administration must be repeated if the travel
period is >5 months (Table 1).
MSM
MSM (both adolescents and adults) should be vaccinated.
Prevaccination testing is not indicated for the vaccination of
adolescents and young adults in this population but might be
warranted for older adults (see Prevaccination Serologic Test-
ing for susceptibility). Studies have suggested that the major-
ity of MSM would accept hepatitis A vaccination if
recommended by their providers (53). Health-care providers
in primary-care and specialty medical settings in which MSM
receive care should offer hepatitis A vaccine to patients at risk.
Implementation strategies to overcome barriers and increase
coverage (e.g., use of standing orders) should be considered.
Users of Injection and Noninjection Drugs
Vaccination is recommended for users of injection and
noninjection illicit drugs. Prevaccination testing is not indi-
cated for the vaccination of adolescent users of illicit drugs
but might be warranted for certain adults. The need might
depend on the particular characteristics of the population of
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drug users, including the type and duration of drug use. Pro-
viders should obtain a thorough history to identify patients
who use or are at risk for using illicit drugs and might benefit
from hepatitis A vaccination. Implementation strategies to
overcome barriers and increase coverage (e.g., use of standing
orders) should be considered.
Persons Who Have Occupational Risk for Infection
Persons who work with HAV-infected primates or with HAV
in a research laboratory setting should be vaccinated. Studies
conducted among U.S. workers exposed to raw sewage do
not indicate increased risk for HAV infection. No other popu-
lations have been demonstrated to be at increased risk for HAV
infection because of occupational exposure.
Persons with Clotting-Factor Disorders
Susceptible persons who are administered clotting-factor
concentrates, especially solvent-detergent–treated preparations,
should receive hepatitis A vaccine. Changes in clotting factor
preparation practices and donor screening have greatly reduced
the risk for hepatitis A for recipients of clotting factors.
Vaccination of Persons with Chronic Liver
Disease
Susceptible persons with chronic liver disease should be vac-
cinated. Available data do not indicate a need for routine vac-
cination of persons with chronic HBV or HCV infections
without evidence of chronic liver disease. Susceptible persons
who are either awaiting or have received liver transplants should
be vaccinated.
Hepatitis A Vaccination During
Outbreaks
The frequency of large communitywide outbreaks has
diminished considerably since implementation of the recom-
mended childhood hepatitis A vaccination programs. Imple-
mentation of the recommendations in this report should
further reduce occurrence of outbreaks. If communitywide
outbreaks occur, accelerated vaccination may be considered
as an additional control measure. Factors to consider in
deciding whether to initiate an outbreak-control vaccination
program include the feasibility of rapidly vaccinating the tar-
get population of children, adolescents, or young adults, and
program cost. Ongoing vaccination of children should be sus-
tained to maintain high levels of immunity and prevent
future epidemics.
Limited outbreaks, especially those involving adults at
increased risk (e.g., illicit drug users or MSM), are likely to
continue to occur until higher vaccine coverage is achieved in
these populations. Vaccination programs to control these out-
breaks have been difficult to implement. Programs to control
hepatitis A outbreaks among users of illicit drugs, especially
methamphetamine, that focused on vaccination in county jails
and similar venues (e.g., court-ordered diversion programs)
have met with some limited success, at least in terms of the
provision of vaccine (57). In general, efforts to control and
prevent hepatitis A outbreaks among adults in these popula-
tions should be focused primarily on initiating and sustaining
routine vaccination of these persons.
The frequency of outbreaks in child care centers has also
decreased in recent years and should continue to decrease with
more widespread vaccination of young children. Limited data
exist regarding the role of hepatitis A vaccine in controlling
outbreaks in these settings. If outbreaks are recognized in child
care centers, use of IG as recommended is effective in limiting
transmission to employees and families of attendees (see
Postexposure Prophylaxis with IG). Previously unvaccinated
children receiving postexposure prophylaxis with IG should
also receive hepatitis A vaccine.
Persons who work as food handlers can contract hepatitis A
and potentially transmit HAV to others. One national eco-
nomic analysis concluded that routine vaccination of all food
handlers would not be economical from a societal or restau-
rant owner’s perspective (197). Nonetheless, to decrease the
frequency of evaluations of food handlers with hepatitis A
and the need for postexposure prophylaxis of patrons, consid-
eration may be given to vaccination of employees who work
in areas where state and local health authorities or private
employers determine that such vaccination is appropriate. Food
handlers who receive hepatitis A vaccine should be provided
with a record of the immunization. Those who do not should
be informed of the signs and symptoms of hepatitis A and
taught food preparation practices that reduce the risk for fecal
contamination.
Postexposure Prophylaxis with IG
Persons who have been recently exposed to HAV and who
have not previously received hepatitis A vaccine should be
administered a single dose of IG (0.02 mL/kg) as soon as pos-
sible. Efficacy when administered >2 weeks after exposure has
not been established. Persons who have been administered
1 dose of hepatitis A vaccine at >1 month before exposure to
HAV do not need IG.
Because hepatitis A cannot be reliably diagnosed on clinical
presentation alone, serologic confirmation of HAV infection
in index patients by IgM anti-HAV testing is recommended
before postexposure treatment of contacts. Screening of con-
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tacts for immunity before administering IG is not recom-
mended because screening would result in delay.
If hepatitis A vaccine is recommended for a person being
administered IG (e.g., a person with a recent exposure but
also an indication for vaccination), it may be administered
simultaneously with IG at a separate anatomic injection site.
Unlike IG, hepatitis A vaccine is not licensed for use as
postexposure prophylaxis. The completion of studies com-
paring IG with hepatitis A vaccine for postexposure prophy-
laxis is needed before vaccine can be recommended in this
setting. IG should be administered to previously unvaccinated
persons in the following situations.
Close Personal Contact
IG should be administered to all previously unvaccinated
household and sexual contacts of persons with serologically
confirmed hepatitis A. In addition, persons who have shared
illicit drugs with a person who has serologically confirmed
hepatitis A should receive IG and hepatitis A vaccine. Con-
sideration should also be given to providing IG to persons
with other types of ongoing, close personal contact with a
person with hepatitis A (e.g., regular babysitting).
Child Care Centers
IG should be administered to all previously unvaccinated
staff and attendees of child care centers or homes if 1) one or
more cases of hepatitis A are recognized in children or
employees or 2) cases are recognized in two or more house-
holds of center attendees. In centers that do not provide care
to children who wear diapers, IG need be administered only
to classroom contacts of an index patient. When an outbreak
occurs (i.e., hepatitis A cases in three or more families), IG
also should be considered for members of households that
have children (center attendees) in diapers. Hepatitis A vac-
cine may be administered at the same time as IG for children
receiving postexposure prophylaxis in child care centers.
Common-Source Exposure
If a food handler receives a diagnosis of hepatitis A, IG should
be administered to other food handlers at the same establish-
ment. Because common-source transmission to patrons is
unlikely, IG administration to patrons typically is not indi-
cated but may be considered if 1) during the time when the
food handler was likely to be infectious, the food handler both
directly handled uncooked foods or foods after cooking and
had diarrhea or poor hygienic practices, and 2) patrons can be
identified and treated <2 weeks after the exposure. In settings
in which repeated exposures to HAV might have occurred
(e.g., institutional cafeterias), stronger consideration of IG use
might be warranted. In the event of a common-source out-
break, IG should not be administered to exposed persons
after cases have begun to occur because the 2-week period
during which IG is effective will have been exceeded.
Schools, Hospitals, and Work Settings
IG is not routinely indicated when a single case occurs in
an elementary or secondary school, an office, or other work
settings, and the source of infection is outside the school or
work setting. Similarly, when a person who has hepatitis A is
admitted to a hospital, staff should not routinely be adminis-
tered IG; instead, careful hygienic practices should be empha-
sized. IG should be administered to persons who have close
contact with index patients if an epidemiologic investigation
indicates HAV transmission has occurred among students in
a school or among patients or between patients and staff in a
hospital.
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Goal and Objectives
This report provides updated recommendations made by the Advisory Committee on Immunization Practices (ACIP) concerning vaccination to prevent hepatitis
A virus (HAV) infection in the United States. The goal of this report is to guide clinical practice and policy development related to the prevention of HAV infection.
Upon completion of this educational activity, the reader should be able to 1) identify recommendations for the routine hepatitis A vaccination of children in the
United States, 2) describe the epidemiology of hepatitis A in selected areas of the United States after implementation of ACIP’s 1996 and 1999 recommendations
for use of hepatitis A vaccine, 3) list the primary target groups for routine hepatitis A vaccination, and 4) describe the characteristics of currently licensed hepatitis
A vaccines.
To receive continuing education credit, please answer all of the following questions.






8. I plan to use these recommendations as the basis for…(Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
9. Overall, the length of the journal report was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.
10. After reading this report, I am confident I can identify
recommendations for the routine hepatitis A vaccination of children






11. After reading this report, I am confident I can describe the
epidemiology of hepatitis A in selected areas of the United States after
implementation of ACIP’s 1996 and 1999 recommendations for use






12. After reading this report, I am confident I can list the primary target






1. Which of the following recommendations are made regarding
children who should be routinely vaccinated or considered for
vaccination? (Indicate all that apply.)
A. All children should receive hepatitis A vaccine at age 1 year (i.e., 12–23
months).
B. States, counties, and communities with existing hepatitis A
vaccination programs for children aged 2–18 years are encouraged to
maintain these programs.
C. In areas without existing hepatitis A vaccination programs, catch-up
vaccination of unvaccinated children aged 2–18 years may be
considered.
D. All of the above.
2. The 2004 national rate of reported cases of hepatitis A (1.9 cases per
100,000 population, representing 5,683 reported cases) was the lowest
ever recorded and was 79% lower than the previously recorded low.
A. True.
B. False.
3. The following persons are at increased risk for HAV infection and
should be routinely vaccinated:
A. Persons traveling to or working in countries that have high or
intermediate levels of HAV infection.
B. Men who have sex with men.
C. Users of illegal drugs (both injecting and noninjecting).
D. Persons who have an occupational risk for infection.
E. Persons who have a clotting-factor disorder.
F. Susceptible persons who have chronic liver disease.
G. All of the above.
4. Recent hepatitis A rates among American Indians and Alaska Natives
represent a 99% decline from the prevaccine era and are now










6. In recent years, the majority of hepatitis A cases have been reported
from states with historically low rates of hepatitis A in which hepatitis
A vaccination of children has not been implemented widely.
A. True.
B. False.















































































































































































































































































































































































































































































































































































































































































































































































































13. After reading this report, I am confident I can describe the













15. The instructional strategies used in this report (text, tables, and






























20. The availability of continuing education credit influenced my
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Correct answers for questions 1–6.
1. D; 2. A; 3. G; 4. A; 5. A; 6. A.






22. Do you feel this course was commercially biased? (Indicate yes or no;
if yes, please explain in the space provided.)
A. Yes.
B. No.
23. How did you learn about the continuing education activity?
A. Internet.






The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge
in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The
body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC’s World-Wide Web server at http://www.cdc.gov/mmwr or from CDC’s
file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government
Printing Office, Washington, DC 20402; telephone 202-512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on
Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material
to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.
All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
All MMWR references are available on the Internet at http://www.cdc.gov/mmwr. Use the search function to find specific articles.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or
their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in
MMWR were current as of the date of publication.
✩U.S. Government Printing Office: 2006-523-056/40038 Region IV ISSN: 1057-5987
